Divalproex Sodium Tablet, Delayed Release
Product Images NDC 72789-353

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 72789-353). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789353 Label (72789353)

Packaging label for Divalproex Sodium delayed-release tablets USP, 250 mg. The label shows the product name, strength, and specifies 100 tablets per container. It includes manufacturer information for Sun Pharmaceutical Industries Ltd., India, and marketer PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label also contains storage instructions, a barcode, lot number, expiration date (05/2025), and instructions for pharmacists to dispense with a medication guide.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Bar chart labeled Figure 1 comparing percentage values between PBO (placebo) and DVPX (divalproex sodium) groups in two studies. Study 1 uses YMRS scale showing 26% for PBO and 60% for DVPX, while Study 2 uses MRS scale showing 29% for PBO and 58% for DVPX.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A cumulative distribution plot comparing percent reduction in CPS rate between Divalproex Sodium (DVPX) and placebo groups. The y-axis shows percent reduction in CPS rate, indicating improvement or worsening, while the x-axis represents percent of patients. Two curves are displayed: a solid line for Divalproex Sodium and a dashed line for placebo.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A line chart labeled Figure 3 depicting the percentage reduction in CPS rate on the y-axis against the percentage of patients on the x-axis. Two lines represent High Dose (solid line) and Low Dose (dashed line) groups. Improvement and Worsening are indicated on the right side with arrows and a No Change line at 0% reduction.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Mean 4-week Migraine Rates' comparing migraine rates for Placebo versus Divalproex Sodium (DVPX) across two studies. The vertical axis represents migraine rates from 0 to 6, with Study 1 bars showing higher rates for Placebo than DVPX, and Study 2 bars showing similar trends with Placebo higher than DVPX.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of Divalproex Sodium showing the molecular arrangement including sodium ion and carboxyl groups in a polymeric form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.